Venetoclax is an anti-BCL2 agent approved in Europe for the treatment of chronic lymphocytic leukemia (CLL) that has shown therapeutic activity in mantle cell lymphoma (MCL) and other hematological malignancies (15–17). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.